Shire submits Vyvanse sNDA for adult ADHD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After launching Vyvanse (lisdexamfetamine dimesylate) last month, Shire submits a supplemental claim for treatment of attention deficit/hyperactivity disorder in adults, the firm announces June 29. The sNDA will receive a standard review. FDA approved Vyvanse for treatment of ADHD in children ages 6-12 in February 2007 (1Pharmaceutical Approvals Monthly March 2007, In Brief), but as a controlled substance it could not be launched until final Drug Enforcement Administration scheduling. DEA announced its concurrence with FDA's recommendation for Schedule II status on May 3, with an effective date of June 4 (2Pharmaceutical Approvals Monthly June 2007, p. 23). The outcome of the sNDA review could affect Shire's plans for a long-acting adult-targeted version of Adderall XR, SPD465 (triple-beaded mixed amphetamine salts), which received an "approvable" letter in May...
You may also be interested in...
Shire adds Vyvanse to ADHD stable
Shire's next-generation attention deficit/hyperactivity disorder drug Vyvanse (lisdexamfetamine dimesylate) clears FDA Feb. 23. The company will attempt to transition patients from Adderall XR to the new formulation before 2009, when Adderall generics are likely to launch. Vyvanse received a second "approvable" letter Dec. 21, but Shire had expected approval by March (1Pharmaceutical Approvals Monthly January 2007, p. 16). Indicated to treat children ages six to 12, the drug was evaluated in that age group in three dosage strengths (30 mg, 50 mg and 70 mg) in a 290-patient Phase III randomized, double-blind, placebo-controlled trial. Vyvanse is the first product to be approved following FDA's Feb. 21 announcement that manufacturers of 15 ADHD drugs would need to include patient medication guides to warn of possible cardiovascular and psychiatric risks...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.